prikaz prve stranice dokumenta Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
  Preuzmi
PDF 2.44 MB
Stručni rad - Stručni rad
Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
Pharmacological Research, 166 (2021); 105499. https://doi.org/10.1016/j.phrs.2021.105499
Banach, Maciej; Penson, Peter E.; Vrablik, Michal; Bunc, Matjaz; Dyrbus, Krzysztof; Fedacko, Jan; Gaita, Dan; Gierlotka, Marek; Jarai, Zoltan; Magda, Stefania Lucia; Margetić, Eduard; Margoczy, Roman; Durak-Nalbantic, Azra; Ostadal, Petr; Pella, Daniel; Trbušić, Matias; Udroiu, Cristian Alexandru; Vlachopoulos, Charalambos; Vulic, Dusko; Fras, Zlatko; Dudek, Dariusz; Reiner, Željko Više autora...

Citirajte ovaj rad

Banach, M., Penson, P. E., Vrablik, M., Bunc, M., Dyrbus, K., Fedacko, J. ... Reiner, Ž. (2021). Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacological Research, 166.. doi: 10.1016/j.phrs.2021.105499

Banach, Maciej, et al. "Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)." Pharmacological Research, vol. 166, 2021. https://doi.org/10.1016/j.phrs.2021.105499

Banach, Maciej, Peter E. Penson, Michal Vrablik, Matjaz Bunc, Krzysztof Dyrbus, Jan Fedacko, Dan Gaita, et al. "Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)." Pharmacological Research 166 (2021). https://doi.org/10.1016/j.phrs.2021.105499

Banach, M., et al. (2021) 'Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)', Pharmacological Research, 166. doi: 10.1016/j.phrs.2021.105499

Banach M, Penson PE, Vrablik M, Bunc M, Dyrbus K, Fedacko J, i sur.. Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacological Research [Internet]. 04.2021. [pristupljeno 15.02.2025.];166. doi: 10.1016/j.phrs.2021.105499

M. Banach, et al., "Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)", Pharmacological Research, vol. 166, Travanj 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:914316. [Citirano: 15.02.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:914316
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)
AutorMaciej Banach
AutorPeter E. Penson
AutorMichal Vrablik
AutorMatjaz Bunc
AutorKrzysztof Dyrbus
AutorJan Fedacko
AutorDan Gaita
AutorMarek Gierlotka
AutorZoltan Jarai
AutorStefania Lucia Magda
AutorEduard Margetić
AutorRoman Margoczy
AutorAzra Durak-Nalbantic
AutorPetr Ostadal
AutorDaniel Pella
AutorMatias Trbušić
AutorCristian Alexandru Udroiu
AutorCharalambos Vlachopoulos
AutorDusko Vulic
AutorZlatko Fras
AutorDariusz Dudek
AutorŽeljko Reiner
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity and mortality across Europe. Much of these diseases burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines are based on the sound premise that with respect to low density lipoprotein cholesterol (LDL-C), "lower is better for longer", and the recent data have strongly emphasized the need of also "the earlier the better". In addition to statins, which have been available for several decades, the availability of ezetimibe and inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) are additional very effective approach to LLT, especially for those at very high and extremely high cardiovascular risk. LLT is initiated as a response to an individual's calculated risk of future ASCVD and is intensified over time in order to meet treatment goals. However, in real-life clinical practice goals are not met in a substantial proportion of patients. This Position Paper complements existing guidelines on the management of lipids in patients following ACS. Bearing in mind the very high risk of further events in ACS, we propose practical solutions focusing on immediate combination therapy in strict clinical scenarios, to improve access and adherence to LLT in these patients. We also define an 'Extremely High Risk' group of individuals following ACS, completing the attempt made in the recent European guidelines, and suggest mechanisms to urgently address lipid-medicated cardiovascular risk in these patients.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeStručni rad - Stručni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaPharmacological Research
Brojčani podacivol. 166, 105499
p-ISSN1043-6618
e-ISSN1096-1186
DOIhttps://doi.org/10.1016/j.phrs.2021.105499
URN:NBNurn:nbn:hr:105:914316
Datum objave publikacije2021-04
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S1043661821000839
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2021-06-29 07:46:40